Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Diabetes Mellitus
Interventions: Phase 1- Introduction to Dexcom G6 CGM; Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Henderson, Nevada

Conditions: Knee Osteoarthritis
Interventions: Femoral Nerve Catheters, Single Shot Femoral Nerve Blocks; Drug
Lead sponsor: Eastern Maine Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Bangor, Maine

Conditions: Metastatic HER2-positive Breast Cancer
Interventions: Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more

Conditions: Anxiety, Hypertension
Interventions: Clonidine Pill, Hydrochlorothiazide; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 79 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Obesity, Childhood
Interventions: iChoose, Family Connections; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 5 Years to 12 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Moderate to Severe Midface Volume Deficit
Interventions: saypha® VOLUME Lidocaine, Juvéderm® Voluma™ XC; Combination Product
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Scottsdale, Arizona • Encino, California • Fremont, California + 13 more

Conditions: Chronic Allergic Conjunctivitis
Interventions: Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Pediatric Brain Tumor
Interventions: Survivor's Journey+; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 25 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Cardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Heart Diseases
Interventions: CABG surgery plus MED, Active Medication Alone, CABG plus MED and SVR; Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anxiety, Distress, Emotional, Effects of Vibration, Healthy
Interventions: Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS), Waitlist Control, Healthy Controls: Substudy Group III, Distressed Workers: Subgroup II; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Oral Iron; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Hypothermia
Interventions: Dynatherm Medical vitalHEAT Temperature Management System vH2, Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN); Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Small Cell Lung Carcinoma
Interventions: JDQ443; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Liver
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Knee Osteoarthritis
Interventions: Total Knee Arthroplasty; Device
Lead sponsor: Canary Medical; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Tampa, Florida • Atlanta, Georgia + 4 more

Conditions: Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
Interventions: Comprehensive Care Plan; Other
Lead sponsor: Valley Anesthesiology Consultants; Other
Eligibility: 12 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Colonoscopy
Interventions: Remimazolam, Midazolam, Placebo; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more

Conditions: Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Interventions: Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging); Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 20 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis, Tuberculosis
Interventions: Not listed
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 40
States / cities: Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more

Conditions: Retinal Vein Occlusions
Interventions: Avastin, Osurdex; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Multiple Sclerosis
Interventions: ponesimod, teriflunomide; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Carlsbad, California • Pomona, California • Denver, Colorado + 7 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Naproxen; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteopenia
Interventions: Oral calcitonin at dinnertime, Oral placebo at dinnertime, Oral calcitonin at bedtime, Oral placebo at bedtime; Drug
Lead sponsor: Tarsa Therapeutics, Inc.; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Walnut Creek, California • Clearwater, Florida • Bethesda, Maryland + 7 more

Search by objective public record fields.

Assessing Non-adjunctive CGM Safety at Home and in New Markets

Comparing Femoral Nerve Catheters to Single Shot Femoral Nerve Blocks for Total Knee Replacement Surgery

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System

A Trial of Two Family-based Childhood Obesity Treatment Programs

Saypha® VOLUME Lidocaine for Midface Augmentation

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

Survivors Journey+

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

Effect of (TaVNS) on Anxiety and Brain Function in Distressed Health Care Workers

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Intraoperative Warming Comparison of Devices

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension

A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis